Owlet (OWLT) Q2 2026: Subscription Revenue Surges 256%, Cementing Platform Transition

August 11, 2026 | By EarningsIQ Research

Owlet’s strategic shift from hardware sales to a subscription-based pediatric health platform is accelerating, driven by robust subscription revenue growth and international expansion. Despite near-term promotional headwinds, the company’s evolving data-driven platform and telehealth initiatives position it for durable recurring revenue. Execution on subscription enrollment innovations and international market penetration underpins Owlet’s path toward a million-plus subscriber base.

Summary

• Subscription Platform Expansion: Owlet is transitioning to a data and services model anchored by its Owlet360 subscription, aiming for a durable subscriber base exceeding one million.
• International Momentum: Strong global sales growth, particularly in Europe, is broadening Owlet’s market footprint and revenue diversification.
• Operational Discipline Amid Competition: Management adopts a cautious outlook for H2 2026 due to aggressive competitor discounting and macroeconomic signals, while investing in margin-enhancing initiatives like WebPay.

Business Overview

Owlet, Inc. is a pioneer in smart infant monitoring, offering FDA-cleared wearable pediatric health devices combined with a digital subscription platform called Owlet360. The company generates revenue primarily from hardware sales—its DreamSoc socks and DreamDuo camera—and increasingly from subscription services that provide ongoing health insights, telehealth, and AI-driven parenting support. Its business segments include hardware sales and subscription services, with growing international operations complementing its core U.S. market.

Performance Analysis

Owlet achieved record quarterly revenue of $33.9 million in Q2 2026, reflecting a 29.9% year-over-year increase fueled by broad-based hardware growth and a 256% surge in subscription revenue to $3.2 million. Subscription now represents a meaningful and expanding portion of total revenue, supported by 130,000 paying subscribers. Gross margin expanded to 54.0% excluding a one-time $3.5 million tariff refund, driven by subscription’s higher margin profile (68.4%) and favorable product mix.

Operating expenses rose 33% to $20.1 million, primarily due to increased marketing spend related to Prime Day promotional timing and severance costs, reflecting investments in customer acquisition and operational restructuring. Adjusted EBITDA excluding tariff refunds improved to $2.9 million from $0.5 million a year ago, signaling improved operational leverage. The company reported a net loss of $0.6 million, a dramatic improvement from a $37.4 million loss in Q2 2025, underscoring progress toward profitability.

• Hardware and Subscription Synergy: Hardware sales remain the primary revenue driver, but subscription growth is reshaping Owlet’s revenue mix toward recurring streams.
• International Sales Surge: International revenue more than tripled year-over-year, with strong sell-through in Europe and emerging markets, highlighting successful global expansion.
• Tariff Refund Impact: A one-time $3.5 million tariff refund boosted gross margin and adjusted EBITDA, but underlying margin improvement also reflects operational gains.

Overall, Owlet’s financial performance reflects the early payoff of its strategic pivot to subscription and international growth, while managing promotional headwinds and investing in scalable customer acquisition.

Executive Commentary

Strategic Positioning

1. Transition to a Data and Services Platform

Owlet is evolving from a hardware-centric company to a subscription-first business model, leveraging its unique pediatric health data to deliver ongoing insights and telehealth services through Owlet360. This platform approach aims to extend customer lifetime value (LTV) by deepening engagement beyond the newborn phase into broader parenting years.

2. Subscription Enrollment Innovations

The rollout of WebPay and upfront subscription enrollment at the point of purchase are critical initiatives to increase subscription attach rates and improve margins by bypassing costly app store fees. Early adoption promises to enhance both customer convenience and economics, supporting sustainable subscription growth.

3. International Market Expansion

Owlet is aggressively expanding in European markets, including Germany, France, and Eastern Europe, where penetration rates are approaching U.S. levels. The company’s global footprint diversification reduces reliance on the U.S. market and taps into larger birth rates and growing demand for pediatric health technology abroad.

4. Telehealth as a Growth Lever

Owlet On Call represents a nascent but promising telehealth initiative, integrating FDA-cleared data with physician access to improve at-home pediatric care. The company envisions multiple service tiers, ultimately embedding telehealth into the subscription offering to drive incremental revenue and stickiness.

5. Competitive Moat via Regulatory Differentiation

The FDA clearance of Owlet’s DreamSoc monitor and Amazon’s enforcement of this requirement create a significant barrier to entry for competitors, potentially reducing discount-driven market share erosion and supporting long-term pricing power.

Key Considerations

Owlet’s Q2 results highlight the company’s successful execution of its subscription platform strategy amidst competitive and macroeconomic challenges. Key considerations for investors include:

• Subscription Growth as a Profitability Driver: Increasing subscription penetration and retention are essential to moving Owlet toward sustained profitability and higher-margin recurring revenue.
• Promotional Timing Impact: The shift of Prime Day promotions into Q2 caused uneven quarter-over-quarter comparisons and competitive discounting that pressured unit sales.
• International Expansion Risks and Opportunities: While international growth is robust, it requires continued investment and regulatory navigation, with potential currency and market risks.
• Operational Efficiency Focus: Management’s commitment to financial discipline and cost control will be critical to balancing growth investments with margin expansion.
• Telehealth Integration Complexity: Scaling telehealth offerings demands careful execution to ensure quality, regulatory compliance, and customer adoption without diluting core subscription economics.

Risks

Owlet faces risks including aggressive competitor discounting, uncertain consumer spending patterns, and reliance on continued regulatory compliance for its FDA-cleared products. The company’s transition to a subscription model depends on sustained customer acquisition and retention, which could be challenged by market saturation or slower-than-expected adoption of new features. Additionally, international expansion exposes Owlet to geopolitical and operational risks that could affect growth.

Forward Outlook

For Q3 2026, Owlet expects sequential and year-over-year revenue declines due to competitor discounting and challenging comparisons from prior product launches. The company reaffirmed full-year 2026 revenue guidance of $118 to $122 million, with gross margin now projected at 53% to 55%, reflecting the one-time tariff refund benefit. Adjusted EBITDA guidance was raised to $10.75 to $12.75 million, also reflecting the tariff refund impact. Management emphasized a cautious approach to the second half, balancing near-term pressures with strategic investments in subscription growth and operational efficiency.

Takeaways

Owlet’s Q2 performance underscores its successful pivot to a subscription-centric model and international growth, supported by regulatory advantages and product innovation. Investors should monitor:

• Subscription Metrics: Growth in subscriber count, retention rates, and average revenue per user (ARPU) will be key indicators of platform traction and revenue durability.
• International Execution: Continued momentum and margin contribution from Europe and emerging markets will validate Owlet’s global expansion strategy.
• Telehealth Development: Progress in integrating telehealth services into Owlet360 could unlock new revenue streams and deepen customer engagement.

Conclusion

Owlet’s Q2 2026 results reflect a company in transition, successfully expanding its subscription platform and international reach while navigating competitive and macroeconomic headwinds. Its unique FDA-cleared product and data-driven services position it well for long-term growth, though execution on subscription adoption and telehealth integration will be critical to realizing its vision of a durable pediatric health platform.

Industry Read-Through

Owlet’s quarterly results highlight broader industry trends toward integrating medical-grade monitoring with digital subscription services, reflecting consumer demand for comprehensive health insights and convenience. The enforcement of regulatory standards by major platforms like Amazon signals increasing barriers for consumer health device entrants, potentially consolidating market leadership among FDA-cleared providers. Additionally, the expansion of telehealth services within pediatric care exemplifies the sector’s shift toward remote, data-driven healthcare delivery, a trend other companies in wearable health technology and telemedicine should closely monitor.

OWLT Healthcare Wearable Medical Devices Subscription Telehealth FDA Clearance International Expansion